TGTX TG Therapeutics Inc.

6.98
+0.15  (+2%)
Previous Close 6.83
Open 6.86
Price To Book 24.07
Market Cap 585416411
Shares 83,870,546
Volume 1,048,388
Short Ratio
Av. Daily Volume 2,236,722

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced November 27, 2017.
TGR-1202 (umbralisib) plus obinutuzumab
Relapsing or refractory Follicular Lymphoma
Phase 2a final data to be presented October 11, 2018. Annualized Relapse Rate (ARR) of 0.07.
TG-1101 (ublituximab)
Relapsing forms of Multiple Sclerosis (RMS)
Phase 3 completion of enrollment announced August 7, 2018. Data due mid-2020.
TG-1101 - ULTIMATE II
Multiple Sclerosis
Phase 1/2 poster at ASH 2017 showed 78% (7 of 9) ORR.
Umbralisib (TGR-1202) + Pembrolizumab + Ublituximab (TG-1101)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 completion of enrollment announced August 7, 2018. Data due mid-2020.
TG-1101 - ULTIMATE I
Multiple Sclerosis
Phase 2/3 MZL cohort met ORR primary endpoint. Data presentation at AACR April 1, 2019; 3pm.
TG-1101 and TGR-1202 - UNITY-NHL study
Non-Hodgkin Lymphoma (NHL)
Phase 3 trial met primary endpoint - March 6, 2017. Data presented at ASCO 2017. BLA to be filed 3Q 2018.
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Noted September 25, 2018 that primary analysis will focus on PFS rather than ORR with data possibly due 2019. DSMB noted March 8, 2019 that trial may continue as planned.
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
Phase 1 updated data released at EHA June 2018. 2 patients (9%) achieved a durable complete remission.
TGR-1202
Myelofibrosis
Phase 1 trial initiation announced February 26, 2019.
TG-1801
Relapsed or Refractory B-cell Lymphoma

Latest News

  1. TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
  2. What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
  3. TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference
  4. TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
  5. Those Who Purchased TG Therapeutics Shares A Year Ago Have A 57% Loss To Show For It
  6. This Is Why TG Therapeutics Stock Soared 65.9% in February
  7. The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
  8. TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings
  9. The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
  10. 3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'
  11. Why These Pharma ETFs Rallied on Thursday
  12. TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
  13. Why TG Therapeutics Stock Skyrocketed 30.5% Today
  14. TG Therapeutics Announces Proposed Public Offering of Common Stock and Closing of $60.0 Million Venture Debt Financing
  15. TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
  16. Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
  17. TG Therapeutics Announces Initiation of Phase I First-in-Human Clinical Trial of its Anti-CD47/CD19 Bispecific Antibody, TG-1801, in Patients with Relapsed or Refractory B-cell Lymphoma
  18. TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
  19. Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
  20. HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?